Literature DB >> 19393627

STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation.

Osamu Ikeda1, Yuto Miyasaka, Yuichi Sekine, Akihiro Mizushima, Ryuta Muromoto, Asuka Nanbo, Akihiko Yoshimura, Tadashi Matsuda.   

Abstract

Signal transducing adaptor protein-2 (STAP-2) is a recently identified adaptor protein that contains Pleckstrin and Src homology 2 (SH2)-like domains as well as a YXXQ motif in its C-terminal region. STAP-2 is also known as breast tumor kinase (Brk) substrate (BKS). Our previous studies revealed that STAP-2 binds to signal transducer and activator of transcription 3 (STAT3) and STAT5, and regulates the signaling pathways downstream of them. In the present study, we identified tyrosine-250 (Tyr250) in STAP-2 as a major site of phosphorylation by Brk, using a series of STAP-2 YF mutants and anti-phospho-STAP-2 Tyr250 antibody. Furthermore, overexpression of the STAP-2 Y250F mutant protein affected Brk-mediated STAT3 activation. Importantly, small-interfering RNA-mediated reduction of endogenous STAP-2 expression decreased Brk-mediated STAT3 activation. Taken together, our findings demonstrate that STAP-2 is phosphorylated at Tyr250 by Brk, and plays an important role in Brk-mediated STAT3 activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393627     DOI: 10.1016/j.bbrc.2009.04.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.

Authors:  Osamu Ikeda; Yuichi Sekine; Akihiro Mizushima; Misa Nakasuji; Yuto Miyasaka; Chikako Yamamoto; Ryuta Muromoto; Asuka Nanbo; Kenji Oritani; Akihiko Yoshimura; Tadashi Matsuda
Journal:  J Biol Chem       Date:  2010-10-07       Impact factor: 5.157

Review 2.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

3.  Differential gene expression between neuropeptide Y expressing neurons of the dorsomedial nucleus of the hypothalamus and the arcuate nucleus: microarray analysis study.

Authors:  Shin Draper; Melissa Kirigiti; Maria Glavas; Bernadette Grayson; C N Angie Chong; Betty Jiang; M Susan Smith; Lori M Zeltser; Kevin L Grove
Journal:  Brain Res       Date:  2010-04-07       Impact factor: 3.252

4.  Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane.

Authors:  Jessica Gierut; Yu Zheng; Wenjun Bie; Robert E Carroll; Susan Ball-Kell; Andrea Haegebarth; Angela L Tyner
Journal:  Gastroenterology       Date:  2011-07-08       Impact factor: 22.682

Review 5.  Signal transducer and activator of transcription 3 regulation by novel binding partners.

Authors:  Tadashi Matsuda; Ryuta Muromoto; Yuichi Sekine; Sumihito Togi; Yuichi Kitai; Shigeyuki Kon; Kenji Oritani
Journal:  World J Biol Chem       Date:  2015-11-26

Review 6.  Brk/PTK6 signaling in normal and cancer cell models.

Authors:  Julie H Ostrander; Andrea R Daniel; Carol A Lange
Journal:  Curr Opin Pharmacol       Date:  2010-09-09       Impact factor: 5.547

7.  PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1.

Authors:  Shin-Ae Kang; Eun-Saem Lee; Hye-Young Yoon; Paul A Randazzo; Seung-Taek Lee
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

Review 8.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

Review 9.  Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer.

Authors:  Yu Zheng; Angela L Tyner
Journal:  Eur J Clin Invest       Date:  2013-02-10       Impact factor: 4.686

10.  TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.

Authors:  Youzhou Sang; Yanxin Li; Lina Song; Angel A Alvarez; Weiwei Zhang; Deguan Lv; Jianming Tang; Feng Liu; Zhijie Chang; Shigetsugu Hatakeyama; Bo Hu; Shi-Yuan Cheng; Haizhong Feng
Journal:  Cancer Res       Date:  2018-01-31       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.